• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·000590.SZ
Share

Guhan Pharmaceutical Group Co., Ltd. Stocks

CN¥ 9.06Last Updated 12.10.2026

Issuer Rating

3/7
Performance

Poor

Risk

Limited

Recommendation

Sell

Market Cap

CN¥ 328.50M

CN¥ 9.06
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guhan Pharmaceutical Group Co., Ltd., along with its various subsidiaries, operates as a prominent Chinese pharmaceutical enterprise. The company focuses on the production and distribution of traditional Chinese medicine (TCM), conventional chemical pharmaceuticals, and health supplements within the domestic market. Its business activities are organized into specific segments, including the manufacturing and sale of traditional Chinese medicine, the manufacturing and sale of Western medicine, and a range of other operations. The company boasts a comprehensive product catalog featuring both prescription and over-the-counter (OTC) drugs. This selection includes tonics and health-boosting preparations, medications for cardiovascular and cerebrovascular conditions, nutritional products for children, cold and flu remedies, and detoxifying agents. Beyond its core manufacturing, Guhan Pharmaceutical is involved in a diverse array of additional services and ventures. These encompass health and nutrition advisory services, the cultivation of Chinese medicinal herbs, extensive medical research and experimental development, planning for cultural and artistic exchanges, general medical consultations, online sales, technology promotion, consulting agent services, outpatient care, and comprehensive pharmaceutical wholesale and retail operations. Founded in 1956, the company is headquartered in Hengyang, China. It was previously known as Tus-Pharmaceutical Group Co., Ltd., officially adopting its current name, Guhan Pharmaceutical Group Co., Ltd., in November 2025.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 15:03

The Nobel Prize in Economics was awarded to the authors of new approaches to crisis management

12.10.2026 14:48

Slow but sure—a tsunami: IMF chief warns that AI is hitting the labor market and government budgets

12.10.2026 14:28

The CEOs of Broadcom and Intel have identified the main challenge facing AI development. It is not a chip shortage.

12.10.2026 13:09

The Saudis announced that they had intercepted new missiles. Riyadh promises stable oil supplies

12.10.2026 12:54

After Anthropic backed out of the deal, Amazon began considering a $7 billion acquisition of an AI startup

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026